Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients

BACKGROUND: Most non‐small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase‐tyrosine kinase inhibitor (ALK‐TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK‐TKI therapies; however, little clinical data ex...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Thorac Cancer
Autori principali: Haratake, Naoki, Seto, Takashi, Takamori, Shinkichi, Toyozawa, Ryo, Nosaki, Kaname, Miura, Naoko, Ohba, Taro, Toyokawa, Gouji, Taguchi, Kenichi, Yamaguchi, Masafumi, Shimokawa, Mototsugu, Takenoyama, Mitsuhiro
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons Australia, Ltd 2019
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718030/
https://ncbi.nlm.nih.gov/pubmed/31338990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13143
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi